Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 577-581

  Furuya, Yuzo ^a   Kawauchi, Yoko ^a   Fuse, Hideki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Apoptosis; Endocrine therapy; Prognostic factors; Proliferation; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMADINONE; FLUTAMIDE; FOSFESTROL; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; NICK END LABELING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOPSY; CELL DIFFERENTIATION; CELL DIVISION; CHLORMADINONE ACETATE; COMBINED MODALITY THERAPY; DIETHYLSTILBESTROL; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0037234049     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Catalona WJ and Scott WW: Carcinoma of the prostate. J Urol 119: 1-8, 1978.
2. Schroder FH: Endocrine treatment of prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds): Campbell's Urology. Philadelphia, WB Saunders Co, 1998, 7th edn, pp 2627-2644.
3. Schulze H, Isaacs JT and Senge T: Inability of complete androgen blockade to increase survival of patients with advanced prostate cancer as compared to standard hormonal therapy. J Urol 137: 909-911, 1987.
4. Isaacs JT, Furuya Y and Berges R: The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 5: 391-400, 1994.
5. Bruckheimer EM and Kyprianou N: Apoptosis in prostate carcinogenesis: a growth regulator and a therapeutic target. Cell Tissue Res 301: 153-162, 2000.
6. Aalatomaa S, Lipponen P, Vesalainen S et al: Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 32: 410-415, 1997.
7. Mcloughlin J, Foster CS, Price P et al: Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Brit J Urol 72: 92-97, 1993.
8. Aihara M, Truong LD, Dunn JK et al: Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 25: 797-801, 1994.
9. Gleason DF, Mellinger GT and the Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64, 1974.
10. Soloway MS, Hardeman SW, Hickey D et al: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988.
11. Kaibuchi T, Furuya Y, Akakura K et al: Changes in cell proliferation and apoptosis during local progression of prostate cancer. Anticancer Res 20: 1135-1140, 2000.
12. Furuya Y, Akimoto S, Akakura K et al: Response of prostate specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol Int 60: 28-32, 1998.
13. Stapleton AMF, Zbell P, Kattan MW et al: Assessment of the biologic markers p53, ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82: 168-175, 1998.
14. Harper ME, Goddard L, Wilson DW et al: Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate 21: 75-84, 1992.
15. Aaltomaa S, Lipponen P, Vesalainen S et al: Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 32: 410-415, 1997.
16. Tu H, Jacobs SC, Borkowski A et al: Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-b1 and bcl-2 expression. Int J Cancer 69: 357-363, 1996.
17. Tanji N, Yokoyama M, Sugimoto T et al: Apoptosis in prostatic adenocarcinomas: a study of relationship to Ki-67 and Bcl-2 protein expression. Anticancer Res 18: 1111-1116, 1998.
18. Stattin P, Westin P, Damber JE et al: Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Brit J Cancer 77: 670-675, 1988.